163 related articles for article (PubMed ID: 3460521)
1. Imipenem-cilastatin in the treatment of methicillin-sensitive and methicillin-resistant Staphylococcus aureus infections.
Fan W; del Busto R; Love M; Markowitz N; Cendrowski C; Cardenas J; Quinn E; Saravolatz L
Antimicrob Agents Chemother; 1986 Jan; 29(1):26-9. PubMed ID: 3460521
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacies of imipenem-cilastatin and vancomycin in experimental aortic valve endocarditis due to methicillin resistant Staphylococcus aureus.
Chandrasekar PH; Levine DP; Price S; Rybak MJ
J Antimicrob Chemother; 1988 Apr; 21(4):461-9. PubMed ID: 3378959
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus infection.
Davis SL; Perri MB; Donabedian SM; Manierski C; Singh A; Vager D; Haque NZ; Speirs K; Muder RR; Robinson-Dunn B; Hayden MK; Zervos MJ
J Clin Microbiol; 2007 Jun; 45(6):1705-11. PubMed ID: 17392441
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of imipenem/cilastatin in endocarditis.
Dickinson G; Rodriguez K; Arcey S; Alea A; Greenman R
Am J Med; 1985 Jun; 78(6A):117-21. PubMed ID: 3859210
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of moderate or severe infections using imipenem/cilastatin. 41 cases based on a multicenter protocol].
Stahl JP; Chavanet P; Robert D; Croize J; Mercatello A; Bru JP; Aguilaniu F; Portier H; Micoud M
Pathol Biol (Paris); 1986 May; 34(5):465-9. PubMed ID: 3534723
[TBL] [Abstract][Full Text] [Related]
6. [Annual changes in isolation of MRSA in our department and chemotherapeutic effect of antibiotics including minocycline against postoperative infections of methicillin-resistant S. aureus].
Yokoyama T; Kodama T; Takesue Y; Fujimoto M; Murakami Y; Sewake H; Imamura Y; Okita M
Jpn J Antibiot; 1990 Jan; 43(1):131-8. PubMed ID: 2348549
[TBL] [Abstract][Full Text] [Related]
7. Imipenem/cilastatin therapy for serious bacterial infections.
Nielsen DM; Katz JR; AhLoy RD; Hansen RS; Meyer RD
Rev Infect Dis; 1985; 7 Suppl 3():S506-12. PubMed ID: 3901214
[TBL] [Abstract][Full Text] [Related]
8. Determination of antimicrobial susceptibility patterns in Staphylococcus aureus strains recovered from patients at two main health facilities in Kabul, Afghanistan.
Naimi HM; Rasekh H; Noori AZ; Bahaduri MA
BMC Infect Dis; 2017 Nov; 17(1):737. PubMed ID: 29187146
[TBL] [Abstract][Full Text] [Related]
9. Early clinical experience with imipenem-cilistatin.
Ellis-Pegler RB; Downey D; Bremner DA
N Z Med J; 1985 Mar; 98(775):188-91. PubMed ID: 3856762
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial susceptibility patterns and characterization of clinical isolates of Staphylococcus aureus in KwaZulu-Natal province, South Africa.
Shittu AO; Lin J
BMC Infect Dis; 2006 Jul; 6():125. PubMed ID: 16875502
[TBL] [Abstract][Full Text] [Related]
11. Rapid detection of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-susceptible Staphylococcus aureus (MSSA) using the KeyPath MRSA/MSSA blood culture test and the BacT/ALERT system in a pediatric population.
Sullivan KV; Turner NN; Roundtree SS; McGowan KL
Arch Pathol Lab Med; 2013 Aug; 137(8):1103-5. PubMed ID: 23899068
[TBL] [Abstract][Full Text] [Related]
12. Antibiotic Resistance in the Treatment of Staphylococcus aureus Keratitis: a 20-Year Review.
Chang VS; Dhaliwal DK; Raju L; Kowalski RP
Cornea; 2015 Jun; 34(6):698-703. PubMed ID: 25811722
[TBL] [Abstract][Full Text] [Related]
13. Imipenem/cilastatin for pediatric infections in hospitalized patients.
Nalin DR; Hart CB; Shih WJ; Aziz MA
Scand J Infect Dis Suppl; 1987; 52():56-64. PubMed ID: 3331043
[TBL] [Abstract][Full Text] [Related]
14. In vitro susceptibility of methicillin-resistant Staphylococcus aureus to imipenem and other antimicrobial agents.
Ishag AJ; Durgham SM; Shibl AM
Chemioterapia; 1987 Aug; 6(4):261-3. PubMed ID: 3477333
[TBL] [Abstract][Full Text] [Related]
15. Comparison of both clinical features and mortality risk associated with bacteremia due to community-acquired methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus.
Wang JL; Chen SY; Wang JT; Wu GH; Chiang WC; Hsueh PR; Chen YC; Chang SC
Clin Infect Dis; 2008 Mar; 46(6):799-806. PubMed ID: 18266610
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes and antibiotic susceptibilities of Staphylococcus aureus endophthalmitis.
Huz JI; Mukkamala K; Pagan IR; Ritterband D; Shah M; Gentile RC; Engelbert M
Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):651-656. PubMed ID: 27757526
[TBL] [Abstract][Full Text] [Related]
17. [In vitro synergism of two-drug combinations among cefamandole, flomoxef and imipenem against MRSA].
Inoue M; Sakurai N; Matsui H; Tsunoda M; Okubo T
Jpn J Antibiot; 1990 Feb; 43(2):233-8. PubMed ID: 2362351
[TBL] [Abstract][Full Text] [Related]
18. The efficacy results and safety profile of imipenem/cilastatin from the clinical research trials.
Calandra GB; Ricci FM; Wang C; Brown KR
J Clin Pharmacol; 1988 Feb; 28(2):120-7. PubMed ID: 3283176
[TBL] [Abstract][Full Text] [Related]
19. Pneumonia treated with imipenem/cilastatin.
Salata RA; Gebhart RL; Palmer DL; Wade BH; Scheld WM; Groschel DH; Wenzel RP; Mandell GL; Duma RJ
Am J Med; 1985 Jun; 78(6A):104-9. PubMed ID: 3859208
[TBL] [Abstract][Full Text] [Related]
20. Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis.
Marangon FB; Miller D; Muallem MS; Romano AC; Alfonso EC
Am J Ophthalmol; 2004 Mar; 137(3):453-8. PubMed ID: 15013867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
